Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Chronic Kidney Disease & Heart Failure Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NR3C2/MR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (LBD/DBD) | NR3C2 LBD & DBD Recombinant Proteins (Ligand Binding Domain and DNA Binding Domain). High purity (>95%), Endotoxin <1EU/µg. Sequence verified. HEK293 expressed. Theoretical MW confirmed by Mass Spec. | View NR3C2 Products |
| Mutant Panel | NR3C2 S810L Constitutive Active Mutant. For mechanistic studies of ligand-independent activation and precision therapeutics. Theoretical MW verified by MS. | View NR3C2 Products |
| Gene Delivery | NR3C2 Promise-ORF / Lentivirus. Full-length ORF for stable reporter cell lines. Puromycin selectable. | View NR3C2 Products |
| Benchmark Ab | Anti-NR3C2/MR (Control Reagent). Recombinant positive control for binding/expression assays. ChIP/IP grade. | View NR3C2 Products |
| Validator | NR3C2/MR siRNA Set. For knockdown verification in cell-based assays. | View NR3C2 Products |
| Selectivity Counter-Screen | NR3C1 (GR) LBD Protein. Human Glucocorticoid Receptor LBD for cross-reactivity evaluation. Critical for selectivity assays. | View NR3C1 Products |
| Pathway Regulator | HSD11B2 Recombinant Protein. 11β-Hydroxysteroid dehydrogenase 2 – regulates cortisol/cortisone conversion and MR activation. | View HSD11B2 Products |
| Trafficking Modulator | NEDD4L (NEDD4-2) Recombinant Protein. E3 ubiquitin ligase regulating MR stability and degradation. | View NEDD4L Products |
| Related Target | CYP11B2. Aldosterone Synthase (Synergistic cardiovascular/renal pathway). | View CYP11B2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear Receptor Selectivity (MR vs GR, AR, PR) | Human MR LBD and GR LBD proteins available with >95% purity; HEK293 expressed for native folding. Sequence Verified by Mass Spec. Homolog panel includes NR3C1, AR, PR. |
| Ligand-Independent Activation | NR3C2 S810L Mutant Protein available – validated sequence for studying constitutive activation mechanisms. |
| Coactivator Recruitment Screening | High-purity LBD domains (>95%) suitable for TR-FRET and AlphaScreen assay development. Minimal aggregate content ensures robust signal-to-noise. |
| Reporter Cell Line Generation | High-titer Lentivirus particles for stable integration of NR3C2 into mammalian reporter systems. |
| Endogenous Hormone Interference | HSD11B2 enzyme protein available for co-incubation studies controlling cortisol activation. |
| Cross-Species Toxicology Evaluation | Human/Mouse/Cyno ortholog MR LBD proteins available with >95% purity. |
| Lack of Controls | Recombinant control proteins and siRNA sets included for specificity checks. |
| False Positives in Screening | Validated siRNA for knockdown verification; Endotoxin controlled (<1 EU/µg). |
Live NR3C2/MR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NR3C2-targeted therapeutics has shifted from first-generation steroidal antagonists (spironolactone, eplerenone) to next-generation non-steroidal selective mineralocorticoid receptor antagonists (sMRAs) such as finerenone (Bayer) and esaxerenone (Daiichi Sankyo/GHC). As first-generation therapies like finerenone prove successful in the clinic for diabetic kidney disease, the next wave of R&D is targeting broader chronic kidney disease (CKD), heart failure, and precision PROTAC degradation strategies to minimize hyperkalemia risks. Key frontiers include:
- Tissue-selective modulation: Dissociating cardiac protective effects from renal sodium retention to address both hypertension and heart failure with preserved ejection fraction (HFpEF).
- Partial agonism (MRPM): Developing MR modulators that retain anti-inflammatory cardiac benefits while minimizing hyperkalemia risk.
- Mutant-specific biology: Understanding rare constitutively active mutants (S810L) causing familial hyperaldosteronism type I (FH-I) for precision therapeutic approaches.
- Combination strategies: Co-administration with SGLT2 inhibitors or GLP-1 agonists to maximize cardiorenal protection and neutralize hyperkalemia risk.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Non-Steroidal Antagonist (sMRA) | Bayer, Daiichi Sankyo, KBP Biosciences, Eisai | CKD with T2D, Heart Failure, Hypertension | Selectivity vs GR (Need NR3C1 protein counter-screen); Coactivator displacement assay |
| Steroidal MRA (Next-generation) | Pfizer, Merck, Takeda | Heart Failure, Primary Aldosteronism | Mutant Binding Assay (Need MR LBD S810L and mutant panel) |
| Partial Agonist (MRPM) | Preclinical (Various) | HFpEF, Cardiac Fibrosis | Cell-based reporter with Lentivirus; Mutant NR3C2 profiling |
| PROTAC / Degrader | Emerging Biotechs | Resistant Hypertension, Primary Aldosteronism | Degradation Validation (Need specific cell-based reporter systems and NEDD4L trafficking tools) |
| Combination Therapy | Bayer, Novo Nordisk, Eli Lilly, AstraZeneca | Cardiorenal Syndrome | Pathway Analysis (Need related targets like CYP11B2, HSD11B2) |
| siRNA / ASO | Early Development | Primary Aldosteronism | NR3C2 siRNA validation sets for knockdown specificity |